Significant Corporate Developments: Hengrui Pharmaceuticals (01276) announced that its adebelisib injection has received a drug clinical trial approval notice. Anjoy Foods (02648) plans to inject an additional RMB 120 million in capital into its Henan subsidiary. Xuanzhu Bio-B (02575) has been included in the list of stocks eligible for Southbound Trading. PegBio Biopharmaceuticals-B (02565) reported one-month clinical observation results from the first-in-human trial of its next-generation GLP-1 (CR059). Changfeng Pharmaceutical (02652) has been included in the list of Hong Kong-listed securities eligible for Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect programs. Binhai Investment (02886) has secured a multi-currency term loan facility of up to USD 45 million and RMB 173 million. Abbisko-B (02256) announced that The Lancet has published the global Phase III MANEUVER study results for Beijiemai®.

Operational Performance: Yuexiu Property (00123) reported cumulative contracted sales of approximately RMB 7.106 billion for the first two months of the year. Mengniu Dairy (02319) expects its annual profit attributable to equity shareholders to be in the range of approximately RMB 1.4 billion to RMB 1.6 billion. Dongfeng Motor Group (00489) recorded cumulative vehicle sales of 228,518 units for the first two months, representing a year-on-year increase of approximately 1.2%. ZJLD Group (02145) issued a positive profit alert, anticipating a 2025 profit of approximately RMB 1.14 billion to RMB 1.16 billion, an increase of about 41.9% to 44.4% compared to the previous year. Longfor Group (00960) achieved total contracted sales of RMB 4.45 billion in the first two months. ZTE Corporation (00763) released its 2025 annual results, showing a net profit attributable to shareholders of RMB 5.618 billion, a decrease of 33.32% year-on-year. Huishang Bank (03698) issued a positive profit forecast, estimating a 2025 net profit of approximately RMB 16.93 billion, an increase of about 6.3% year-on-year. Sun Hung Kai & Co. (00086) announced a positive profit alert, expecting its 2025 comprehensive profit attributable to shareholders to be no less than HKD 1.5 billion.